Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy

N Engl J Med. 2018 May 17;378(20):1947-1948. doi: 10.1056/NEJMc1803181.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Disease Progression
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy*
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor
  • Nivolumab